Lv2
180 积分 2023-05-23 加入
Advances in Novel Targeted Therapies for Pancreatic Adenocarcinoma
2个月前
已完结
Advances in Novel Targeted Therapies for Pancreatic Adenocarcinoma
2个月前
已完结
Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial
3个月前
已完结
The present and future of bispecific antibodies for cancer therapy
5个月前
已完结
Phase 1a dose escalation study of ivonescimab (AK112/SMT112), an antiPD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors
5个月前
已完结
PD1 × VEGF blocking bispecifics for cancer draw big backing
5个月前
已完结
Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study
6个月前
已完结
97P Asian subgroup analysis of the phase III LEAP-017 trial of lenvatinib plus pembrolizumab vs standard-of-care in previously treated metastatic colorectal cancer (mCRC)
6个月前
已关闭
Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR)
6个月前
已完结
Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer
6个月前
已完结
皖公网安备34019202002308
